There is one clinical trial.
The investigators aim to characterise Coronavirus Disease 2019 (COVID-19) in every age group. On the one hand, emphasis is put on the initial presentation, clinical course, outcome and the therapy used. On the other hand further investigations regarding viral and bacterial coinfections, and response of the immune system will be conducted. This study should serve to improve the understanding of COVID-19, to identify risk factors for a severe clinical course and to obtain further insights into pathophysiology of this new infectious disease.
Description: Description of clinical course of COVID-19 in children, adolescents and adultsMeasure: Clinical course of COVID-19 Time: 10/2020
Description: Measurement of specific IgM- and IgG-antibody productionMeasure: Analysis of development of antibodies to SARS-CoV-2 Time: 10/2020
Description: Estimation of viral load at initial presentation and after two weeksMeasure: Estimation of viral load Time: 10/2020
Description: A Multiplex PCR will be conducted to test for the most common respiratroy viruses. A naso- and oropharyngeal swab will be used for thisMeasure: Detection of viral coinfections Time: 10/2020
Description: Determination of cytokine and chemokine concentrations in serum by ELISA.Measure: Measurement of cytokine and chemokine response Time: 12/2020
Description: Characterisation of virus-host-interaction by HLA-typingMeasure: Characterisation of virus-host-interaction Time: 12/2020
Description: Identification of disease patterns in proteome by analysis of the proteome in serum and urineMeasure: Identification of disease patterns in proteome Time: 12/2020
Description: Detection of change in lymphocyte subtypes in blood and bronchoalveolar lavageMeasure: Analysis of change in lymphocyte subtypes Time: 10/2020
Description: Analysis of histological changes in severe lung disease by lung biopsyMeasure: Analysis of histological changes in severe lung disease Time: 12/2020
Description: A pharyngeal swab will be cultured to check for bacteria residing in the upper airways. Additionally, a blood culture will serve to detect bacteremiaMeasure: Detection of bacterial coinfections Time: 10/2020
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports